1.Masters GA，Temin S，Azzoli CG，et al. Systemic Therapy for Stage Ⅳ Non-Small-Cell Lung Cancer：American Society of Clinical Oncology Clinical Practice Guideline Update ［J］. J Clin Oncol，2015，33（30）：3488-3515.

2.王征，武晓楠，石远凯，等.细胞学标本表皮生长因子受体基因突变检测的规范化流程［J］.中华肿瘤杂志，2014，36（7）：516-521.

3.Qi WX，Sun YJ，Shen Z，et al. Risk of interstitial lung disease associated with EGFR-TKIs in advanced nonsmall-cell lung cancer：a meta-analysis of 24 phase Ⅲ clinical trials ［J］. J Chemother，2015，27（1）：40-51.

4.Ando M，Okamoto I，Yamamoto N，et al. Predictive factors for interstitial lung disease，antitumor response，and survival in non-small-cell lung cancer patients treated with gefitinib ［J］. J Clin Oncol，2006，24（16）：2549-2556.

5.Akamatsu H，Inoue A，Mitsudomi T，et al. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer：combined analysis of two Phase Ⅲ trials（NEJ 002 and WJTOG 3405）［J］. Jpn J Clin Oncol，2013，43（6）：664-668.

6.Cohen MH，Williams GA，Sridhara R，et al. FDA drug approval summary：Gefitinib（ZD1839）（Iressa）tablets［J］.Oncologist，2003，8（4）：303-306.

7.Kudoh S，Kato H，Nishiwaki Y，et al. Interstitial lung disease in Japanese patients with lung cancer：a cohort and nested case-control study ［J］. Am J Respir Crit Care Med，2008，177（12）：1348-1357.

8.Yoshimura A，Gemma A，Kudo S. Interstitial lung disease induced by gefitinib - the final report of a specialist committee ［J］. Japanese Journal of Lung Cancer，2003，43（7）：927-932.

9.Zhang X，Li H，Zhu M，et al. Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma：A case report and review of the literature ［J］. Oncol Lett，2015，9（5）：2419-2421.

10.Koma Y1，Matsuoka H，Yoshimatsu H，et al. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease：a case report and literature review ［J］. Int J Clin Pharmacol Ther，2012，50（10）：760-764.